1-800-526-8630
1 of 4
FEATURED COMPANIES
- Echo Pharmaceuticals
- GW Pharmaceuticals
- INSYS Therapeutics, Inc
- Jenrin Discovery
- One World Cannabis
- MORE
'Cannabinoid Receptor Type 1 (CB1) Antagonist - Pipeline Insight, 2018' reportoffers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Cannabinoid Receptor Type 1 (CB1) Antagonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:
Pipeline Therapeutics assessment of products for Cannabinoid Receptor Type 1 (CB1) Antagonist
The report assesses the active Cannabinoid Receptor Type 1 (CB1) Antagonist pipeline products by developmental stage, product type, molecule type, and administration route.
Methodology:
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Scope of the report:
READ MORE
Pipeline Products covered across the following Developmental Stages:
- Clinical
- Non-clinical
- Inactive: Discontinued and/or Dormant
Pipeline Therapeutics assessment of products for Cannabinoid Receptor Type 1 (CB1) Antagonist
The report assesses the active Cannabinoid Receptor Type 1 (CB1) Antagonist pipeline products by developmental stage, product type, molecule type, and administration route.
Methodology:
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Scope of the report:
- Provides a snapshot of the therapeutics pipeline activity for Cannabinoid Receptor Type 1 (CB1) Antagonist
- Features the Cannabinoid Receptor Type 1 (CB1) Antagonist pipeline across the complete product development cycle including all clinical and non-clinical stages
- Offers detailed therapeutic product profiles of Cannabinoid Receptor Type 1 (CB1) Antagonist with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
- Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
- Coverage of dormant and discontinued pipeline projects across Cannabinoid Receptor Type 1 (CB1) Antagonist
- Establish a comprehensive understanding of the current pipeline scenario across Cannabinoid Receptor Type 1 (CB1) Antagonist to formulate effective R&D strategies
- Assess challenges and opportunities that influence Cannabinoid Receptor Type 1 (CB1) Antagonist research & development (R&D)
- Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
- Identify and understand the sought after therapy areas and indications for Cannabinoid Receptor Type 1 (CB1) Antagonist
- Identify the product attributes and use it for target finding, drug repurposing, and precision medicine
- Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Cannabinoid Receptor Type 1 (CB1) Antagonist to enhance and expand business potential and scope
- Plan prospective mergers and acquisitions effectively by identifying key players in this area and their most promising pipeline therapeutics and developmental progress
- Our extensive domain knowledge on therapy areas supports the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
Note: Product cover images may vary from those shown
2 of 4
FEATURED COMPANIES
- Echo Pharmaceuticals
- GW Pharmaceuticals
- INSYS Therapeutics, Inc
- Jenrin Discovery
- One World Cannabis
- MORE
1. Report Introduction
2. Cannabinoid Receptor Type 1 (CB1) Antagonist - Overview
3. Pipeline Therapeutics
5. Cannabinoid Receptor Type 1 (CB1) Antagonist Pipeline Products in Clinical Stages
5.1 Drug Name : Company Name
6. Cannabinoid Receptor Type 1 (CB1) Antagonist Pipeline Products in Non-clinical Stages
6.1 Drug Name : Company Name
7. Therapeutic Assessment: Active Products
8.1 Drug Name : Company Name
Report Methodology
Consulting Services
Disclaimer
List of Tables:
Table 1: Total Pipeline Products for Cannabinoid Receptor Type 1 (CB1) Antagonist
Table 2: Cannabinoid Receptor Type 1 (CB1) Antagonist Therapeutic Products in Clinical Stages
Table 3: Cannabinoid Receptor Type 1 (CB1) Antagonist Therapeutic Products in Non-clinical Stages
Table 4: Pipeline Assessment by Route of Administration
Table 5: Pipeline Assessment by Stage and Route of Administration
Table 6: Pipeline Assessment by Molecule Type
Table 7: Pipeline Assessment by Stage and Molecule Type
Table 8: Discontinued Products
Table 9: Dormant Products
List of Figures:
Figures 1: Total Products for Cannabinoid Receptor Type 1 (CB1) Antagonist
Figure 2: Cannabinoid Receptor Type 1 (CB1) Antagonist Therapeutic Products in Clinical Stages
Figure 3: Cannabinoid Receptor Type 1 (CB1) Antagonist Therapeutic Products in Non-clinical Stages
Figure 4: Pipeline Analysis by Route of Administration
Figure 5: Pipeline Analysis by Stage and Route of Administration
Figure 6: Pipeline Analysis by Molecule Type
Figure 7: Pipeline Analysis by Stage and Molecule Type
Figure 8: Discontinued Products
Figure 9: Dormant Products
2. Cannabinoid Receptor Type 1 (CB1) Antagonist - Overview
3. Pipeline Therapeutics
- An Overview of Pipeline Products for Cannabinoid Receptor Type 1 (CB1) Antagonist
5. Cannabinoid Receptor Type 1 (CB1) Antagonist Pipeline Products in Clinical Stages
5.1 Drug Name : Company Name
- Product Description
- Research and Development
- Product Development Activities
6. Cannabinoid Receptor Type 1 (CB1) Antagonist Pipeline Products in Non-clinical Stages
6.1 Drug Name : Company Name
- Product Description
- Research and Development
- Product Development Activities
7. Therapeutic Assessment: Active Products
- Pipeline Assessment by Route of Administration
- Pipeline Assessment by Stage and Route of Administration
- Pipeline Assessment by Molecule Type
- Pipeline Assessment by Stage and Molecule Type
8.1 Drug Name : Company Name
- Product Description
- Research and Development
- Product Development Activities
- Reason for dormancy/discontinuation
Report Methodology
Consulting Services
Disclaimer
List of Tables:
Table 1: Total Pipeline Products for Cannabinoid Receptor Type 1 (CB1) Antagonist
Table 2: Cannabinoid Receptor Type 1 (CB1) Antagonist Therapeutic Products in Clinical Stages
Table 3: Cannabinoid Receptor Type 1 (CB1) Antagonist Therapeutic Products in Non-clinical Stages
Table 4: Pipeline Assessment by Route of Administration
Table 5: Pipeline Assessment by Stage and Route of Administration
Table 6: Pipeline Assessment by Molecule Type
Table 7: Pipeline Assessment by Stage and Molecule Type
Table 8: Discontinued Products
Table 9: Dormant Products
List of Figures:
Figures 1: Total Products for Cannabinoid Receptor Type 1 (CB1) Antagonist
Figure 2: Cannabinoid Receptor Type 1 (CB1) Antagonist Therapeutic Products in Clinical Stages
Figure 3: Cannabinoid Receptor Type 1 (CB1) Antagonist Therapeutic Products in Non-clinical Stages
Figure 4: Pipeline Analysis by Route of Administration
Figure 5: Pipeline Analysis by Stage and Route of Administration
Figure 6: Pipeline Analysis by Molecule Type
Figure 7: Pipeline Analysis by Stage and Molecule Type
Figure 8: Discontinued Products
Figure 9: Dormant Products
Note: Product cover images may vary from those shown
3 of 4
LOADING...
4 of 4
- Jenrin Discovery
- One World Cannabis
- GW Pharmaceuticals
- INSYS Therapeutics, Inc
- Echo Pharmaceuticals
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
